Reported Earlier, VolitionRX Says On Dec 29, Received $13M In Milestone Payments From Heska, Post License And Supply Deal Entered Into On March 28, 2022
Portfolio Pulse from Benzinga Newsdesk
VolitionRx Limited received $13M in milestone payments from Heska Corporation as part of their License and Supply Agreement. The payment was for the successful transfer of the Nu.Q Vet Cancer Test to Heska's Element i+ Immunodiagnostic Analyzer, now called the 'Heska Nu.Q Vet Canine Cancer Screen and Monitor' test.
January 02, 2024 | 4:43 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Heska Corporation made a $13M milestone payment to VolitionRx, indicating a successful collaboration and enhancement of their product offerings.
Heska's milestone payment to VolitionRx demonstrates a fruitful collaboration and the successful expansion of their product line with the Nu.Q Vet Cancer Test. This investment could be seen as a commitment to innovation and may positively influence Heska's stock in the short term.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
VolitionRx Limited received a significant milestone payment of $13M from Heska, indicating progress and potential revenue growth from their partnership.
The receipt of a $13M milestone payment is a strong positive signal for VolitionRx, suggesting successful product integration and a solid partnership with Heska. This could lead to increased investor confidence and potential revenue, positively impacting the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100